Clinical significance of RCAS1 as a biomarker of ovarian cancer.
Clinical significance of RCAS1 as a biomarker of ovarian cancer.
复制标题
RCAS1 作为卵巢癌生物标志物的临床意义。
DOI：
10.3892/or.17.3.623
复制
发表时间：
2007
期刊：
影响因子：
4.2
通讯作者：
H. Nakano
中科院分区：
文献类型：
--
作者：
K. Sonoda;S. Miyamoto;Fusanori Yotsumoto;H. Yagi;M. Nakashima;Takeshi Watanabe;H. Nakano
RCAS 1（SiSo细胞上表达的受体结合癌抗原）的表达与包括卵巢癌在内的各种恶性肿瘤的晚期疾病相关。RCAS 1在胞外结构域的蛋白水解裂解（胞外结构域脱落）产生可溶性RCAS 1。虽然RCAS 1可以诱导正常人外周血淋巴细胞凋亡，但其在卵巢癌患者中的临床意义和生物学功能尚不清楚。在这里，我们评估血清RCAS 1浓度，以阐明其在卵巢癌中的临床意义和生物活性。采用酶联免疫吸附法（ELISA）检测了75例健康献血员和97例卵巢良性肿瘤患者（36例）、61例卵巢癌患者（61例）血清中RCAS 1的浓度。我们通过统计学方法将RCAS 1值与患者的临床病理变量相关联。我们通过血清样品的WST-1测定来评估表达推定的RCAS 1受体的K562细胞的生长抑制，以阐明RCAS 1的生物活性。卵巢癌患者血清RCAS 1水平显著高于健康献血员和卵巢癌患者（P<0.05）。卵巢肿瘤和卵巢癌患者的RCAS 1水平根据组织学亚型有显著差异（P分别为0.0266和0.0074）。RCAS 1值也与治疗反应显著相关（P<0.001）。WST-1检测显示患者血清可诱导K562细胞生长抑制，但在免疫耗竭RCAS 1后，这种作用部分恢复（P=0.0074）。RCAS 1可能是卵巢癌的生物标志物，因为它具有预测治疗结果和抑制免疫细胞生长的能力。
Expression of RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is associated with advanced disease of various malignancies including ovarian cancer. Proteolytic cleavage of RCAS1 at extracellular domains (ectodomain shedding) yields soluble RCAS1. Although RCAS1 can induce apoptosis in normal peripheral lymphocytes, its clinical significance and biologic function in ovarian cancer patients are unclear. Here, we evaluated serum RCAS1 concentrations to clarify its clinical significance and biologic activity in ovarian cancer. Via ELISA, we measured serum RCAS1 concentrations in samples from 75 healthy blood donors and 97 patients, 36 with ovarian benign tumor and 61 with ovarian cancer. We correlated via statistical means the RCAS1 values with patients' clinicopathologic variables. We assessed inhibition of growth of K562 cells, which express the putative RCAS1 receptor, via WST-1 assay of serum samples to clarify RCAS1's biologic activity. Ovarian cancer patients had significantly higher serum RCAS1 concentrations than did healthy blood donors and ovarian tumor patients (P<0.05). RCAS1 level was significantly different according to histologic subtype for both ovarian tumor and cancer patients (P=0.0266 and 0.0074, respectively). RCAS1 values were also significantly associated with response to treatment (P<0.001). The WST-1 assay showed that patients' serum induced K562 cell growth inhibition, but this effect partially recovered after immunodepletion of RCAS1 (P=0.0074). RCAS1 may be a biomarker of ovarian cancer by virtue of its ability to predict results of treatment and inhibit immune cell growth.
影响因子：
158.5
作者：
Zhang, L;Conejo-Garcia, JR;Coukos, G
通讯作者：
Coukos, G
胰腺癌中可溶性 CD95 配体的产生和促凋亡活性。
DOI：
--
发表时间：
2000
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Bellone,G;Smirne,C;Carbone,A;Mareschi,K;Dughera,L;Farina,EC;Alabiso,O;Valente,G;Emanuelli,G;Rodeck,U
通讯作者：
Rodeck,U